Association between tocilizumab treatment of hyperinflammatory patients with COVID-19 in a critical care setting and elevated incidence of hospital-acquired bacterial and invasive fungal infections

BACKGROUND: Tocilizumab is an interleukin-6 inhibitor that reduces mortality and the need for invasive mechanical ventilation, while increasing the possibility of successful hospital discharge for hyperinflammatory patients with severe coronavirus disease 2019 (COVID-19). No increase in adverse even...

Descripción completa

Detalles Bibliográficos
Autores principales: Minihan, B., McAuliffe, E., Powell, J., Wong, S.L., Wilkie, K., Murphy, C., Maher, A., Power, L., O'Connell, N.H., Dunne, C.P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of The Healthcare Infection Society. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9033628/
https://www.ncbi.nlm.nih.gov/pubmed/35472487
http://dx.doi.org/10.1016/j.jhin.2022.04.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9033628/
https://www.ncbi.nlm.nih.gov/pubmed/35472487
http://dx.doi.org/10.1016/j.jhin.2022.04.007

Ejemplares similares